Completed PHASE2 INTERVENTIONAL 1-arm NCT01379534

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Sponsor: Novartis Pharmaceuticals

Conditions Endometrial Cancer Second-line Treatment Solid Tumors and Advanced Endometrial Cancer VEGF

Interventions TKI258

Updated 7 times since 2017 Last updated: May 2, 2015 Started: Nov 30, 2011 Primary completion: Mar 31, 2014 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01379534, this PHASE2 trial focuses on Endometrial Cancer and Second-line Treatment and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

*see Various Departments*, United States , Asheville, United States , Barcelona, Spain , Bedford, United States , Belo Horizonte, Brazil , Boston, United States , Candiolo, Italy , Chattanooga, United States , Córdoba, Spain , Durham, United States and 30 more locations